FDA Inspection 1298166 — Hybio Pharmaceutical Co., Ltd.

Hybio Pharmaceutical Co., Ltd. — FEI 3026377169

The FDA completed an inspection of Hybio Pharmaceutical Co., Ltd. on Dec 5, 2025 in Shenzhen. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
Dec 5, 2025
Fiscal Year
2026
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Shenzhen (China)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.